Source: International Congress 2015 – New models for treating airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Andreas Kuttler (Basel, Switzerland), Andreas Kuttler, Thomas Dimke. Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics. Eur Respir J 2015; 46: Suppl. 59, 3582

Member's Comments

No comment yet.

Related content which might interest you: Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Small airways targeting of inhaled steroids for severe therapy resistant asthma in children Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment Source: Eur Respir J 2008; 31: 1145-1147 Year: 2008 Methodological issues in therapeutic trials of COPD Source: Eur Respir J 2008; 31: 927-933 Year: 2008 Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Reproducibility of inhaler use and pulmonary drug deposition in COPD Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - PG13 Asthma: pathology and treatment Year: 2009 Targeting airway inflammation in asthma: current and future therapies Source: Annual Congress 2009 - MP7 - Targeting airway inflammation in asthma: current and future therapies Year: 2009 Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD Source: International Congress 2016 – Non-inflammatory COPD monitoring Year: 2016 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Airway inflammation in asthma: current and future targets and therapies Source: Breathe 2010; 6: 245-252 Year: 2010 Effects of ciclesonide on the management of stable COPD with airway eosinophilia Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Human small airway-on-a-chip: A novel microphysiological system to model lung inflammation, accelerate drug development and enable inhalational toxico-analysis Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Effect of drugs with pleiotropic properties on tone of pulmonary arteries and bronchi in obstructive lung pathology model Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003 Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006 B2-adrenoceptor genotype16 influences airway calibre but not hyperresponsiveness in asthmatics using regular B2-agonist in addition to inhaled corticosteroids Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 A novel biophysical simulation model predicts consistent lung delivery of QVA149, glycopyrronium and indacaterol via the Breezhaler® device Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Bronchial asthma: New approach to airways functional diagnostics Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012